Professor Allan Young

Declaration of Interests

  1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
  2. No
  3. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
  4. No
  5. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
  6. No
  7. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
  8. Johnson & Johnson & Livanova
  9. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
  10. Acted as an expert witness to GSK
  11. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
  12. Janssen, Compass, Livanova
  13. Have you, in the past three years, had membership of the speakers' bureau for any company?
  14. No
  15. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
  16. Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders Astrazenaca, Eli Lilly, Janssen, Lundbeck, Sunovion, Servier, Livanova, Sage, Sandoz
  17. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
  18. No
  19. Have you, in the past three years, recruited patients for industry-sponsored studies?
  20. Janssen, COMPASS
  21. If there is anything else you feel it necessary to disclose, please provide details below:
  22. Employed by King’s College London; Honorary Consultant SLaM (NHS UK) Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders Astrazenaca, Eli Lilly, Janssen, Lundbeck, Sunovion, Servier, Livanova

    No share holdings in pharmaceutical companies Lead Investigator for Embolden Study (AZ), BCI Neuroplasticity study and Aripiprazole Mania Study Investigator initiated studies from AZ, Eli Lilly, Lundbeck, Wyeth Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK)

Form completed on 27th August 2019